ArticleTissue engineering and regenerative medicine2026
Optimal IFN-γ Priming and Therapeutic Efficacy of 3D-Cultured Human Umbilical Cord-Derived Mesenchymal Stem Cells.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study focuses on addressing the challenges associated with temporomandibular joint osteoarthritis (TMJOA), a condition currently considered incurable. Osteoarthritis (OA) is a degenerative disease of cartilage and tissues that affects the temporomandibular joint (TMJ). The potential of interferon-γ (IFN-γ)-primed three-dimensional (3D) spheroids of umbilical cord-derived mesenchymal stem cells (UC-MSCs) was investigated as a therapeutic intervention for TMJOA. This research aims to confirm that enhanced 3D UC-MSC spheroids are more effective than their two-dimensional (2D) counterparts.
methodsEffective conditions for IFN-γ-primed 3D spheroids in the treatment of temporomandibular joint osteoarthritis (TMJOA) were determined. The therapeutic potential was confirmed by co-culturing with synovium-derived cells from patients with temporomandibular disorder (TMD-SDCs). The therapeutic efficacy was confirmed by injecting IFN-γ-primed 3D spheroids into rats with TMJOA.
resultsCo-culturing TMD-SDCs with IFN-γ-primed 3D UC-MSC spheroids resulted in significantly improved regenerative and anti-inflammatory effects compared to co-cultures with 2D UC-MSCs. Validation in TMJOA rats further supported the promising effects of IFN-γ-primed 3D spheroids of UC-MSCs. The 3D spheroids group showed rapid recovery based on micro-computed tomography images, histology images, and pain response.
conclusionMSCs were enhanced using cytokine priming and 3D spheroid culture. We successfully established the effective priming conditions for the therapeutic application of IFN-γ-primed 3D spheroids. The findings suggest their potential benefits in the treatment of TMJOA which is currently incurable and inform further advancements in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.